Targeting glutamatergic synapses in Parkinson's disease

Current Opinion in Pharmacology

Volumn 20, Issue , 2015, Pages 24-28

  Gardoni, Fabrizio ^a   Di Luca, Monica ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMANTADINE; GLUTAMATE RECEPTOR; KAINIC ACID RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TOPIRAMATE; ANTIPARKINSON AGENT; IONOTROPIC RECEPTOR;

ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CORPUS STRIATUM; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DYSKINESIA; HUMAN; LOCOMOTION; MOTOR DYSFUNCTION; NEUROMODULATION; NEUROTRANSMISSION; PARKINSON DISEASE; PATHOGENESIS; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPTIC TRANSMISSION; ANIMAL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE; RECEPTORS, IONOTROPIC GLUTAMATE; SYNAPTIC TRANSMISSION;

EID: 84911366337     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.10.011     Document Type: Review

References (50)

1. Fearnley JM, Lees AJ: Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
2. Calabresi P, Picconi B, Tozzi A, Di Filippo M: Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007, 30:211-219.
3. Blandini F, Armentero MT: Animal models of Parkinson's disease. FEBS J 2012, 279:1156-1166.
4. Morin N, Jourdain VA, Di Paolo T: Modeling dyskinesia in animal models of Parkinson disease. Exp Neurol 2014, 256:105-116.
5. Mellone M, Gardoni F: Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system. Eur J Pharmacol 2013, 719:75-83.
6. Dunah AW, Standaert DG: Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 2001, 21:5546-5558.
7. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG: Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 2000, 57:342-352.
8. Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, Cattabeni F, Di Luca M, Calabresi P: A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia . J Neurosci 2006, 26:2914-2922.
9. Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG: Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease . Neuropharmacology 2005, 48:503-516.
10. Paillé V, Picconi B, Bagetta V, Ghiglieri V, Sgobio C, Di Filippo M, Viscomi MT, Giampà C, Fusco FR, Gardoni F et al.: Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 2010, 30:14182-14193.
11. Calabresi P, Pisani A, Mercuri NB, Bernardi G: Long-term potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur J Neurosci 1992, 4:929-935.
12. 2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 2004, 24:5283-5291.
13. Nash JE, Johnston TH, Collingridge GL, Garner CC, Brotchie JM: Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia . FASEB J 2005, 19:583-585.
14. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, Tenesa A, Kusel VI, Sheehan P, Eaaswarkhanth M et al.: Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genetics 2011, 7:e1002237.
15. Ryan TJ, Kopanitsa MV, Indersmitten T, Nithianantharajah J, Afinowi NO, Pettit C, Stanford LE, Sprengel R, Saksida LM, Bussey TJ et al.: Evolution of GluN2A/B cytoplasmic domains diversified vertebrate synaptic plasticity and behavior. Nat Neurosci 2013, 16:25-32.
16. Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ: Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 2010, 67:294-307.
17. Cragg SJ: Meaningful silences: how dopamine listens to the ACh pause. Trends Neurosci 2006, 29:125-131.
18. Bloomfield C, O'Donnell P, French SJ, Totterdell S: Cholinergic neurons of the adult rat striatum are immunoreactive for glutamatergic N-methyl-d-aspartate 2D but not N-methyl-d-aspartate 2C receptor subunits . Neuroscience 2007, 150:639-646.
19. Zhang X, Feng ZJ, Chergui K: GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease. J Neurochem 2014, 129:581-590.
20. Feng ZJ, Zhang X, Chergui K: Allosteric modulation of NMDA receptors alters neurotransmission in the striatum of a mouse model of Parkinson's disease. Exp Neurol 2014, 255:154-160.
21. Hadj Tahar A, Gregoire L, Darre A, Belanger N, Meltzer L, Bedard PJ: Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis 2004, 15:171-176.
22. Loschmann PA, De Groote C, Smith L, Wullner U, Fischer G, Kemp JA, Jenner P, Klockgether T: Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 2004, 187:86-93.
23. Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR: Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2000, 165:136-142.
24. Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD: NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemiparkinsonian rats. Neuropharmacology 2004, 47:184-194.
25. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM: The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP lesioned marmoset model of Parkinson's disease. Exp Neurol 2004, 188:471-479.
26. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bedard PJ, Di Paolo T: Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse 2006, 60:239-250.
27. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA: Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 2009, 330:227-235.
28. Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, Jamerson B, Menniti FS, Landen JW: Effects of a NR2B selective NMDA glutamate antagonist CP-101,606, on dyskinesia and Parkinsonism. Mov Disord 2008, 23:1860-1866.
29. Gardoni F, Sgobio C, Pendolino V, Calabresi P, Di Luca M, Picconi B: Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias . Neurobiol Aging 2012, 33:2138-2144.
30. Da Silva-Junior FP, Braga-Neto P, Sueli Monte F, de Bruin VM: Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005, 11:449-452.
31. Elahi B, Phielipp N, Chen R: N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci 2012, 39:465-472.
32. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E et al.: Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010, 25:1357-1363.
33. Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M et al.: Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014, 82:300-307.
34. Moreau C, Delval A, Tiffreau V, Defebvre L, Dujardin K, Duhamel A, Petyt G, Hossein-Foucher C, Blum D, Sablonnière B et al.: Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 2013, 84:552-555.
35. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R: Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999, 22:273-276.
36. Varanese S, Howard J, Di Rocco A: NMDA antagonist memantine improves levodopa-induced dyskinesias and "onoff" phenomena in Parkinson's disease. Mov Disord 2010, 25:508-510.
37. Betarbet R, Porter RH, Greenamyre JT: GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation. J Neurochem 2000, 74:1166-1174.
38. Ba M, Kong M, Yang H, Ma G, Lu G, Chen S, Liu Z: Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats. Neurochem Res 2006, 31:1337-1347.
39. Bernard V, Gardiol A, Faucheux B, Bloch B, Agid Y, Hirsch EC: Expression of glutamate receptors in the human and rat basal ganglia: Effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion . J Comp Neurol 1996, 368:553-568.
40. Wachtel H, Kunow M, Loschmann PA: NBQX (6-nitro-sulfamoyl-benzo-quinoxalinedione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci Lett 1992, 142:179-182.
41. Klockgether T, Turski L, Honore T, Zhang ZM, Gash DM, Kurlan R, Greenamyre JT: The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991, 30:717-723.
42. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys . Neurology 2000, 54:1589-1595.
43. Marin C, Jiménez A, Bonastre M, Vila M, Agid Y, Hirsch EC, Tolosa E: LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse 2001, 42:40-47.
44. Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E et al. : Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord 2010, 25:896-905.
45. Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Mouradian MM, Oertel WH, Olanow CW, Poewe W et al.: Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord 2012, 27:284-288.
46. Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A et al. : Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 2012, 35:15-20.
47. Angehagen M, Rönnbäck L, Hansson E, Ben-Menachem E: Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem 2005, 94:1124-1130.
48. Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM: Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord 2005, 20:403-409.
49. Kobylecki C, Hill MP, Crossman AR, Ravenscroft P: Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov Disord 2011, 26:2354-2363.
50. Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA: Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2014, 240:452-455.